Received: 27 July 2018 | Revised: 28 August 2018 | Accepted: 1 September 2018

DOI: 10.1111/dom.13522

WILEY

ORIGINAL ARTICLE

Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis

Dan Siskind PhD[1,2] | Margaret Hahn MD[3,4] | Christoph U. Correll MD[5,6,7] | Anders Fink-Jensen DMSc[8,9] | Anthony W. Russell PhD[2,10] | Nikolaj Bak PhD[11] | Brian V. Broberg PhD[11] | Julie Larsen MD[8,12] | Pelle L. Ishøy MD [11] | Tina Vilsbøll DMSc[9,13] | Filip K. Knop MD[9,13,14] | Steve Kisely PhD[1,2] | Bjørn H. Ebdrup MD[9,11]

[1]Metro South Addiction and Mental Health Service, Brisbane, Australia

[2]School of Medicine, University of Queensland, Brisbane, Australia

[3]Centre for Addiction and Mental Health, Toronto, Canada

[4]Department of Psychiatry, University of Toronto, Toronto, Canada

[5]Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, New York

[6]Hofstra Northwell School of Medicine, Department of Psychiatry and Molecular Medicine, Hempstead, New York

[7]Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany

[8]Psychiatric Centre Copenhagen, Rigshospitalet, Mental Health Services – Capital Region of Denmark, Copenhagen, Denmark

[9]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[10]Department of Endocrinology, Princess Alexandra Hospital, Brisbane, Australia

[11]Centre for Neuropsychiatric Schizophrenia Research & Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark

[12]Novo Nordisk A/S, Research and Development, Søborg, Denmark

[13]Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

[14]Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence
Dan Siskind PhD, c/- MIRT, Level 2 Mental Health, 228 Logan Road, Woolloongabba 4102, Australia.
Email: d.siskind@uq.edu.au

Funding information
D. S. is partially supported by an Australian National Mental Health and Research Council Early Career Fellowship. M. H. is supported by Canadian Institutes of Health Research, Centre of Addiction Mental Health Foundation, and The Banting & Best Diabetes Centre. B. H. E. is partially supported by the Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (R13-A1349, R25-A2701 and R155-2013-16 337).

Aims: To evaluate if glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce antipsychotic-associated body weight gain in patients with schizophrenia, when compared to controls.

Materials and methods: We systematically searched PubMed/EMBASE/PsycINFO/Cochrane using the search terms '(antipsychotic and GLP-1RA)'. Individual participant data from studies randomizing patients to GLP-1RA or control were meta-analysed. The primary outcome was difference in body weight between GLP-1RA and control; secondary outcomes included cardio-metabolic variables and adverse drug reactions (ADRs). Multiple linear regression was conducted including sex, age, psychosis severity, metabolic variable, ADRs, and GLP-1RA agent.

Results: Three studies (exenatide once-weekly = 2; liraglutide once-daily = 1) provided participant-level data (n = 164, age = 40.0 ± 11.1 years, body weight = 105.8 ± 20.8 kg). After 16.2 ± 4.0 weeks of treatment, body weight loss was 3.71 kg (95% CI = 2.44-4.99 kg) greater for GLP-1RA versus control ($p < 0.001$), number-needed-to-treat ≥5% body weight loss = 3.8 (95% CI = 2.6-7.2). Waist circumference, body mass index, HbA1c, fasting glucose and visceral adiposity were each significantly lower with GLP-1RA. Sex, age, psychosis severity, nausea, any ADR, and GLP-1RA agent did not significantly impact outcomes. Body weight loss with GLP-1RAs was greater for clozapine/olanzapine-treated patients (n = 141) than other antipsychotics (n = 27) (4.70 kg, 95% CI = 3.13-6.27 vs. 1.5 kg, 95% CI = −1.47-4.47) ($p < 0.001$). Nausea was

more common with GLP-1RAs than control (53.6% vs. 27.5%, p = 0.002, number-needed-to-harm = 3.8).

Conclusion: GLP-1RAs are effective and tolerable for antipsychotic-associated body weight gain, particularly clozapine/olanzapine-treated patients. With few included patients, further studies are required before making routine use recommendations for GLP-1RAs.

KEYWORDS

antipsychotics, body weight loss, cardiovascular risk, GLP-1RAs, obesity, schizophrenia

1 | INTRODUCTION

The life expectancy for patients with schizophrenia is more than 14-20 years shorter than for the general population,[1,2] with 35% of excess deaths attributable to cardiovascular disease and diabetes.[3] Patients with schizophrenia are at increased risk of developing cardiometabolic disease, mediated by or coincident with obesity, for several reasons including a genetic predisposition for developing diabetes, reduced physical activity, poor diet and the use of antipsychotic medications.[4,5]

Although the underlying mechanisms have not been fully elucidated, it is well-established that antipsychotic medications can lead to obesity, with clozapine and olanzapine having the greatest propensity for body weight gain.[6] Among patients with schizophrenia, about half of those on clozapine and a third of those on olanzapine have metabolic syndrome.[7]

Body weight gain is associated with poorer quality of life,[8] reduced social engagement,[9] and is the most distressing side effect reported to mental health helplines.[10] Body weight gain also reinforces patients' negative views of themselves and may compromise adherence with treatment.[10] Furthermore, being overweight or obese increases the risk of all-cause mortality with an association between body weight and higher mortality risk.[11,12]

The current evidence for interventions addressing antipsychotic-associated obesity is limited. Physical activity interventions are compromised by low rates of uptake and acceptability,[13] while many pharmacological treatments can result in unacceptable adverse events.[14] For instance, sibutramine was withdrawn because of cardiovascular risks,[15] while rimonabant was removed because of increased risk of depression, anxiety and suicide.[16] Orlistat is associated with poor adherence because of steatorrhoea.[17] Finally, there is only modest (and heterogeneous) body weight loss following the addition of metformin[18,19] or topiramate[20] for obese and overweight patients on antipsychotics and/or those at risk for antipsychotic body weight gain.[14]

As a result of these limitations, there has been increasing interest in glucagon-like peptide-1 receptor agonists (GLP-1RAs) to counteract the body weight gain associated with antipsychotic treatment in general,[21] and clozapine and olanzapine treatment in particular.[22,23] Glucagon-like peptide-1 (GLP-1) is an endogenous peptide, synthesized in the intestinal mucosa,[24] which stimulates insulin secretion and decreases glucagon secretion in a glucose-dependent manner. It also delays gastric emptying and lowers food intake by promoting satiety.[25]

GLP-1RAs have well-established glucose- and weight-lowering properties in patients with[23] and without[26] type 2 diabetes. GLP-1RA treatment is also associated with a lower risk of major adverse cardiovascular endpoints (composite endpoint including cardiovascular-related mortality, non-fatal myocardial infarction, and non-fatal stroke).[27] In addition to daily injections, several GLP-1RAs are now available as weekly injections, which may improve adherence among patients with schizophrenia.

To our knowledge, prior to conducting the comprehensive systematic review, at least three individual trials investigating the effect of GLP-1RAs (exenatide once-weekly or liraglutide once-daily) on antipsychotic-associated obesity[28–30] had been published. A meta-analysis of participant-level data has the potential to identify whether the effects of GLP-1RAs vary for different antipsychotics and also to examine the influence of more clinically relevant participant-related factors than is possible in a meta-analysis of study-level data.

In this study, we tested the hypotheses that

- GLP-1RAs would be superior to the control conditions for body weight loss, as well as all other anthropometric and cardiometabolic outcomes;
- patients treated with clozapine or olanzapine would experience greater body weight loss with GLP-1RAs.

2 | MATERIALS AND METHODS

2.1 | Protocol and registration

This study was registered with PROSPERO (CRD42017079791).[31] We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations for the background, search strategy, methods, results, discussion and conclusions.[32] Ethical approval was not required as all the included data had been previously published.

2.2 | Search strategy

The following databases were searched from inception to 24 October 2017: PubMed, PsycInfo, Embase, and the Cochrane Schizophrenia Group's Trials Register. Hand searches of references listed in included

studies and other key publications were also conducted. Studies were limited to humans. Search terms included terms for antipsychotics and GLP-1RAs. There were no language limitations. PubMed search terms are provided in Table S1 (see the supporting information for this article).

2.3 | Eligibility criteria and study selection

We included all randomized controlled trials of patients on antipsychotic medications who were overweight or obese where a GLP-1RA was compared with placebo or usual care. All studies were independently screened at the title and abstract level by two authors (D. S. and M. H.). Studies that met the inclusion criteria on title and abstract review, or that could not be excluded on the basis of information provided in the abstract, were reviewed at full text level.

2.4 | Data collection process

Authors of the included studies provided access to de-identified individual participant data. Key authors of the included studies are also co-authors of this meta-analysis. These data were collated and analysed with validation by the corresponding authors of the included studies. Quality assessment was conducted by an author not involved in the included studies (M. H.).

2.5 | Outcomes

The primary outcome was the difference in endpoint body weight adjusted for baseline body weight and study between the GLP-1RA arm and control arm. We analysed the following secondary outcomes in the same way: metabolic syndrome components (waist circumference, blood pressure [BP], HDL, LDL, triglycerides [TGs] and fasting plasma glucose [FPG]), body mass index (BMI), HbA1c, homeostatic model assessment (HoMA), insulin, visceral fat and android-to-gynoid ratio (android adipose tissue surrounds the abdomen, chest, shoulder and nape of the neck, while gynoid adipose tissue surrounds the hips, breasts and thighs).

Psychosis severity for individual patients was based on published inter-scale linkage thresholds for the PANSS, BPRS and GCI.[33,34]

2.6 | Study quality

We assessed study quality using criteria adapted from the Cochrane Collaboration guidelines[32]: (a) selection bias (random sequence generation and allocation concealment); (b) performance bias; (c) detection bias; (d) attrition bias; (e) reporting bias; and (f) other sources of potential bias including pharmaceutical company funding. Studies were deemed to be of low quality if they had three or more elements with a high risk of bias, while those of high quality had four or more elements with a low risk of bias.

2.7 | Statistical analyses

We conducted a one-step meta-analysis on individual participant data, where data from all included studies were modelled simultaneously, while adjusting for clustering of patients within included studies.[35] The primary and secondary outcomes were analysed as differences in endpoint values between intervention and control, and adjusted for baseline value and study as a random effect using ANCOVA with Bonferroni correction on SPSS version 24 for Mac OS. Where individual patient data were missing, we used the modified intention-to-treat model,[29] where the last valid value after the baseline value was carried forward.

We performed multiple linear regressions with endpoint variable as the dependent variable, including the baseline variable and, respectively, each of the following co-variables: demographics (age, sex), psychosis severity, metabolic variables (body weight, BMI, waist circumference, HbA1c, fasting blood glucose, HDL, LDL, TGs, systolic blood pressure [SBP], diastolic blood pressure [DSP], HoMA, insulin) and treatment variables (treatment arm, nausea, any adverse drug reaction and GLP-1RA agent). If any covariates were significant then they were all included in a multiple linear regression, using backward elimination. Adjusted R^2 of the final model was calculated.

We conducted sensitivity analyses to explore the impact of the specific antipsychotic used (patients on clozapine and/or olanzapine vs. patients on other antipsychotics) on treatment arm and endpoint metabolic variables, adjusted for the baseline variable, and conducted a meta-analysis for each metabolic variable using RevMan 5.3. We also carried out a sensitivity analysis by excluding patients with type 2 diabetes.

Chi-square tests were conducted on the proportion of patients in the GLP-1RA and control groups who achieved ≥5% and ≥7% body weight loss. Number-needed-to-treat (NNT) was calculated for the proportion of patients with ≥5% or ≥7% body weight loss by dividing one by the risk difference.

BMI was categorized as per WHO categories (overweight: 25-29.9, obese class I: 30-34.9, obese class II: 35-39.9, obese class III: 40 and above),[36] and the proportion of GLP-1RA-treated patients and controls who shifted between categories from baseline to endpoint was analysed using a chi-square test.

FPG was categorized as per ADA categories (normoglycaemic <5.6 mmoL/L, impaired FPG 5.6-6.9 mmoL/L, type 2 diabetes >6.9 mmoL/L). Chi-square tests between baseline and endpoint FPG categories were conducted for total participants, and those in the GLP-1RA and control arms.

Adverse drug reactions (ADRs) were compared among treatment and control groups using chi-square tests with data available on nausea, diarrhoea, vomiting, other ADRs and any ADR, and a number-needed-to-harm was calculated for ADRs that were significantly different among GLP-1RAs and controls by dividing one by the risk difference. A regression analysis for body weight, adjusted for baseline body weight, study and nausea, was conducted to assess any potential impact of nausea as a mediating factor in body weight change.

2.8 | Publication bias

If the meta-analyses included 10 or more studies, we planned to test for publication bias using funnel plot asymmetry where low P values suggest publication bias.[37]

3 | RESULTS

3.1 | Study selection

Our search identified 56 unique articles. Of these, 43 were excluded at title and abstract level, leaving 13 articles for review at full text level. Three articles met the inclusion criteria[28–30] with a total of 168 patients (GLP-1RA = 84, control = 84). Reasons for exclusion at full text level are provided in Supporting Information Figure S1 and Table S2 (see the supporting information for this article).

3.2 | Study characteristics

Studies were conducted in Denmark (n = 2) and in Australia (n = 1) (Table 1). Duration ranged from 12 to 24 weeks (mean 16.2 weeks, SD 4.0). Two studies used exenatide 2 mg subcutaneously (s.c.) once-weekly,[28,30] and one study used liraglutide 1.8 mg s.c. once-daily,[29] the standard maximum doses used for diabetes.[38] All studies examined GLP-1RA for people on antipsychotic medications, with no notable changes in antipsychotic doses among participants. One study was restricted to participants receiving clozapine and olanzapine,[29] and another to clozapine alone.[30] The third study included a naturalistic patient sample treated with clozapine, olanzapine, aripiprazole, risperidone, paliperidone, quetiapine, ziprasidone, amisulpride and sertindole.[28] After initial publication, an erratum on corrected metabolic blood markers was published for the third study, and these data were used in the current meta-analysis.[39] Two studies were blinded and placebo-controlled,[28,29] while the third was open label.[30] All studies were of adults aged 18-65 years (mean 40.0 years, SD 11.1), 58.3% were male, and the mean BMI of participants was 35.4 kg/m^2 (SD 5.7). All studies included patients with schizophrenia, while two also included schizoaffective disorder.[28,30] One study also included patients with type 2 diabetes,[30] while the other two specifically excluded type 2 diabetes.[28,29] One study required patients to have impaired glucose tolerance.[29] All studies provided data on body weight, BMI, FPG, HDL, TGs, SBP, DSP and HbA1c. Two studies provided data on insulin and HoMA,[29,30] and two on android/gynoid ratio and visceral adiposity.[28,29] Two studies (n = 97 and n = 28) showed significant effect on their primary outcome,[29,30] while the third one (n = 43) was equivocal.[28] Baseline characteristics of the combined dataset are provided in Table 2. All studies were rated to be of high quality (Supporting Information Table S3).

3.3 | Primary outcome

The mean adjusted difference in endpoint body weight among intervention and control groups was 3.71 kg lower for the intervention groups (2.44-4.99 kg, 95% CI) (Table 3). This was a statistically significant difference for treatment arm ($p < 0.001$), but not for study ($p = 0.430$).

3.4 | Secondary outcomes

Reductions in waist circumference, BMI, HbA1c, FPG, LDL and visceral fat were all significantly different between treatment and control (p values <0.001 to 0.03). Lower LDL and DSP were associated with study effect (Table 3).

3.5 | Linear regression

Treatment arm and the baseline variable were statistically significant in the multiple linear regressions of endpoint body weight, BMI and HbA1c (Supplementary Appendix A). Treatment arm, the baseline variable and the additional metabolic variable(s) provided in parentheses were statistically significant for endpoint waist circumference (baseline weight), endpoint FPG (baseline HbA1c), endpoint LDL (baseline TGs), endpoint TGs (baseline waist circumference) and endpoint visceral fat (baseline insulin).

The variables (in parentheses) were significantly associated with the outcome; however, treatment type was not associated with changes in the following variables: endpoint HDL (baseline HDL), endpoint SBP (baseline SBP and DBP), DBP (baseline DBP and android/gynoid ratio), HoMA (baseline insulin and visceral fat), insulin (baseline insulin and visceral fat) and android/gynoid ratio (baseline android/gynoid ratio and TGs).

Age, sex, psychosis severity, baseline SBP, nausea, any ADR and GLP-1RA agent were not significant in any of the linear regressions of endpoint variables. Adjusted R^2 for the multiple linear regressions ranged from 0.284 for SBP to 0.958 for body weight (Supplementary Appendix A).

3.6 | Sensitivity analyses

For the sensitivity analysis by antipsychotic, patients on clozapine and/or olanzapine (n = 141) had a statistically significant reduction in body weight with GLP-1RAs (mean 4.70 kg, 3.13-6.27 kg, 95% CI), while those on other antipsychotics (n = 27) did not have statistically significant change in body weight (mean 1.5 kg, 1.47-4.47 kg, 95% CI). The difference between these two groups was statistically significant ($p < 0.001$). This pattern of statistically significant change in metabolic variables among patients on clozapine and/or olanzapine, but not other antipsychotics, was also seen for waist circumference, BMI, FPG and visceral fat. Both patients on clozapine and/or olanzapine, and those on other antipsychotics, had a statistically significant reduction in HbA1c (Figure 1, Supporting Information in Table S4). When patients only on clozapine were examined (n = 113), they had a 4.90 kg greater body weight loss (3.16-6.64 kg, 95% CI) with GLP-1RAs compared with controls. When patients only on olanzapine were examined (n = 25), they had a 4.70 kg greater body weight loss (1.15-8.25 kg, 95% CI) with GLP-1RAs compared with controls. The difference in comparative body weight loss between clozapine and olanzapine was not statistically significant ($p = 0.845$).

When patients with type 2 diabetes were excluded, reduction in body weight with GLP-1RAs remained statistically significant (3.85 kg, 2.54-5.15 kg, 95% CI).

3.7 | Percentage change in body weight

A significantly greater proportion of patients on GLP-1RA treatment than controls had a body weight loss of ≥5% (36.9% vs. 10.7%,

TABLE 1 Included randomized studies

Authors (year)	Location	Duration (weeks)	Key inclusion criteria	GLP-1RA agent	Frequency	Control	Included antipsychotics	Number of participants (GLP-1RA/control)	% completed (GLP-1RA/control)	Gender: % male (GLP-1RA/control)	Age, years: mean (SD) (GLP-1RA/control)
Ishøy et al. (2017)[28]	Denmark	12	18-65 yrs old; schizophrenia and schizoaffective disorder; BMI > 30; no type 2 diabetes	Exenatide 2 mg s.c.	Weekly	Placebo	Clozapine, olanzapine, aripiprazole, risperidone, paliperidone, quetiapine, ziprasidone, amisulpride and sertindole	23/20	95.7/90	47.8/45.0	37.1 (10.7)/ 34.4 (10.6)
Larsen et al. (2017)[29]	Denmark	16	18-65 yrs old; schizophrenia; BMI > 27; FPG 6.1–6.9 mmol/L or OGTT > 140 mg/dL; no type 2 diabetes	Liraglutide 1.8 mg s.c.	Daily	Placebo	Clozapine and olanzapine	47/50	95.7/100	63.8/60.0	42.1 (10.7)/ 43.0 (10.5)
Siskind et al. (2017)[30]	Australia	24	18-65 yrs old; schizophrenia and schizoaffective disorder; BMI 30-45; ±type 2 diabetes	Exenatide 2 mg s.c.	Weekly	Usual care	Clozapine	14/14	100/100	78.6/50.0	39.9 (14.0)/ 35.7 (8.2)
Total		Mean: 16.2, SD 4.0						84/84	96.4/97.6	61.9/54.8	40.3 (11.4)/ 39.7 (10.8)

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; s.c., subcutaneous.

TABLE 2 Baseline characteristics

Characteristic	N	Mean	SD
Age	168	40.0	11.1
Body weight (kg)	168	105.8	20.8
BMI (kg/m^2)	168	35.4	5.7
Waist circumference (cm)	167	119.1	13.9
HbA1c (IFCC)	168	36.7	4.7
FPG (mmol/L)	168	5.7	0.7
HDL (mmol/L)	168	1.1	0.3
LDL (mmol/L)	166	3.0	1.0
TGs (mmol/L)	168	2.4	1.4
SBP (mm Hg)	167	125.5	12.0
DBP (mm Hg)	167	82.6	9.6
HoMA	167	6.7	3.3
Insulin (pmol/L)	167	182.0	83.4
Visceral fat (gm)	110	2061.4	914.2
Android/gynoid ratio	138	1.2	0.2
Sex (male)	168	n = 98	58.3%

Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose (mg/dL = mmol/L*18); HbA1c, haemoglobin A1c (NGSP = (0.09148*IFCC) + 2.152); HDL, high-density lipoprotein cholesterol (mg/dL = mmol/L*38.6); HoMA, homeostatic model assessment; IFFC, International Federation of Clinical Chemistry; LDL, low-density lipoprotein cholesterol (mg/dL = mmol/L*38.6); NGSP, National Glycohaemoglobin Standardization Programme insulin (mU/L = pmol/L*0.144); SBP, systolic blood pressure; TGs, triglycerides (mg/dL = mmol/L*88.5).

p < 0.001) and ≥ 7% (19.0% vs. 6.0%, p = 0.010). The NNT to achieve ≥5% body weight loss was 3.8 (2.6 to 7.2, 95% CI), while for ≥7% the NNT was 7.7 (4.4 to 31.8, 95% CI).

3.8 | Shift in BMI category

Among patients on GLP-1RAs, 15 (17.9%) shifted down a BMI category, 69 (82.1%) remained in the same category, and none increased a category, while among controls seven (8.4%) shifted down a category, 72 (86.7%) remained in the same category, and four (2.4%) increased a category (χ^2 6.967, 2° of freedom, p = 0.031) (Supporting Information Table S5).

3.9 | Shift in FPG category

Among those with impaired FPG, 26 of 38 (68.4%) participants on GLP-1RAs had normal FPG at endpoint, while only 9 of 38 (23.7%) participants in the control arms had normal FPG at endpoint. Changes in FPG categories are provided in Supporting Information Table S6.

3.10 | Adverse events

Patients on GLP-1RAs reported significantly more nausea compared with controls (53.6% vs. 27.5%, p = 0.002), with a number needed to harm of 3.8 (2.4 to 9.7, 95% CI). Neither the presence of any ADR (76.8% vs. 62.9%, p = 0.073), diarrhoea, vomiting, nor other ADRs were significantly different between the two groups (Supporting Information Table S7). Nausea did not significantly impact the regression model for weight.

TABLE 3 Outcome data

Variable[a]	N	Mean difference GLP-1RA vs. control	SE	Treatment effect		Study effect	
				F value	p-value	F value	p-value
Body weight (kg)	168	−3.71	0.65	33.19	<0.001	0.85	0.430
Waist circumference (cm)	167	−3.00	0.68	19.24	<0.001	2.05	0.132
BMI (kg/m^2)	168	−1.19	0.22	30.25	<0.001	1.13	0.326
HbA1c (IFCC)	166	−3.25	0.66	24.54	<0.001	1.28	0.281
FPG (mmol/L)	166	−0.45	0.09	24.89	<0.001	1.54	0.218
HDL (mmol/L)	166	−0.01	0.02	0.33	0.566	2.92	0.034
LDL (mmol/L)	162	−0.17	0.08	4.82	0.030	3.10	0.048
TG (mmol/L)	166	−0.24	0.12	3.73	0.055	0.68	0.508
SBP (mm Hg)	160	−1.89	1.61	1.39	0.241	0.94	0.392
DBP (mm Hg)	160	−1.91	1.17	2.68	0.104	5.84	0.004
HoMA	163	−0.58	0.59	0.96	0.328	1.98	0.142
Insulin (pmol/L)	163	4.59	12.93	0.13	0.723	1.65	0.196
Android/gynoid ratio	131	−0.006	0.014	0.16	0.692	0.002	0.963
Visceral fat (gm)	97	−177.51	68.71	6.67	0.011	2.92	0.091

Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose (mg/dL = mmol/L*18); HbA1c, haemoglobin A1c (NGSP = (0.09148*IFCC) + 2.152); HDL, high-density lipoprotein cholesterol (mg/dL = mmol/l*38.6); HoMA, homeostatic model assessment insulin (mU/L = pmol/L*0.144); IFCC, International Federation of Clinical Chemistry; LDL, low-density lipoprotein cholesterol (mg/dL = mmol/l*38.6); NGSP, National Glycohaemoglobin Standardization Programme; SBP, systolic blood pressure; TGs, triglycerides (mg/dL = mmol/L*88.5).
[a] ANCOVA endpoint value adjusted for baseline value and study.

3.11 | Publication bias

We were unable to assess publication bias, as no analyses included 10 or more studies.

4 | DISCUSSION

This systematic review and patient-level meta-analysis suggests that GLP-1RAs can induce a clinically meaningful body weight loss in patients with schizophrenia on antipsychotic medications who are overweight or obese. Patients in the intervention arm lost 3.7 kg more body weight than controls. The NNT to achieve a body weight loss of at least 5% (considered clinically meaningful) was 3.8, while for loss of at least 7%, the NNT was 7.7. GLP-1RA treatment was also associated with greater reductions in BMI, FPG, HbA1c and visceral fat. Body weight loss was greatest for those on clozapine and/or olanzapine compared with other antipsychotics. Age, sex, psychosis severity, nausea, any ADR and GLP-1RA agent did not affect body weight or other metabolic variables.

In terms of adverse events, nausea was more common in the GLP-1RA group, but was not associated with greater body weight loss, and thus unlikely to explain the findings. Antipsychotics, including clozapine and olanzapine, have antiemetic properties,[40,41] which may have mitigated this adverse event. In addition, GLP-1RAs are not hepatically metabolized by cytochrome P450, and as such unlikely to interfere with elimination of antipsychotics.[42]

Our findings are consistent with data in non-psychiatrically ill patients with[23] and without type 2 diabetes.[26] There is increasing acknowledgment of the role of GLP-1RAs as an efficacious pharmacological management strategy for the management of obesity, with suggestions that they are under-utilized in the general population.[43]

Our finding of a reduction in visceral adiposity is also important, as this is an independent risk factor for cardiovascular disease,[44] diabetes[45] and death.[46] This is particularly relevant in schizophrenia, where antipsychotic use is both associated with increases in visceral fat and subsequent metabolic syndrome.[47]

The improvements in FPG and HbA1c associated with GLP-1RA treatment are also of clinical importance, given the high rates of glucose intolerance (55%) and impaired FPG (21%) in patients on clozapine or other second-generation antipsychotics.[48,49] Over one third of patients on clozapine develop type 2 diabetes.[50] In turn, there is a higher mortality among those with serious mental illness and type 2 diabetes than those diagnosed with either type 2 diabetes alone, or serious mental illness alone.[51,52] This finding highlights the advantages of body weight loss medications that are also approved antihyperglycaemic drugs with proven reductions in cardiovascular mortality in patients with high-risk type 2 diabetes.[27]

Differences in endpoint body weight between GLP-1RA treatment and control interventions were greater for patients on clozapine and/or olanzapine, which is consistent with preclinical findings on olanzapine's and clozapine's disruption of the GLP-1RA pathway.[22] This result is important, as clozapine remains the only antipsychotic indicated for patients with treatment-resistant schizophrenia, and has the best evidence for managing positive symptoms[53] and reducing hospitalizations[54] in this population. Body weight gain can be both a barrier to commencement of clozapine and a reason for its discontinuation. Our finding of a body weight loss of almost 5 kg more than in the control group among patients on clozapine was significantly greater than that reported for metformin in a recent meta-analysis of people on clozapine[55] (−3.1, −4.9 to −1.4 kg, 95% CI) (p = 0.024). The potential superiority of GLP-1RAs over metformin is also supported by preclinical models. For instance, GLP-1RAs normalize



HbA1c - Haemoglobin A1c
FPG - Fasting plasma glucose
HDL – High density lipoprotein cholesterol
LDL – High density lipoprotein cholesterol
TG – Triglycerides
SBP – Systolic blood pressure
DBP – Diastolic blood pressure
HOMA – Homeostatic Model Assessment

FIGURE 1 Forest plot of standardized mean difference of metabolic variables by antipsychotic

glucose tolerance and decrease body weight in rats treated with clozapine, providing mechanistic justification of their therapeutic potential in this context.[22] By contrast, metformin only partially attenuates glucose dysregulation in animal models of antipsychotic metabolic abnormalities.[56] To date, there have been no head-to-head studies of the effects of GLP-1RAs versus metformin on body weight loss among overweight patients on antipsychotics.

We were not able to include data on non-alcoholic fatty liver disease (NAFLD). NAFLD is a precursor for the development of incident type 2 diabetes and metabolic syndrome[57] and has a mutual and bi-

directional relationship with these disease entities.[58] There is recent evidence for the efficacy of liraglutide for non-alcoholic steatohepatitis.[59] Future studies of GLP-1RAs should include measures of NAFLD.

A key strength of this study is the use of individual participant data. This approach allowed for consistent analytic techniques across studies, notably endpoint values adjusted for baseline values, as recommended by the European Medicines Agency.[60] It also allowed sensitivity analyses by specific variables, notably antipsychotic, age, sex and study duration, and for correlations between change in BMI and baseline BMI.

There are also limitations to this study. There were differences in study inclusion criteria. Although all studies used overweight or obesity as inclusion criteria, one study specifically recruited patients with prediabetes, while another also included patients with type 2 diabetes. Only one study included patients who were not on clozapine or olanzapine, and these patients may have differed in baseline characteristics. This limits both the power and the certainty of differences in the effect of GLP-1RAs on patients who were not on clozapine or olanzapine. One study was not blinded, increasing the risk of bias; however, sensitivity analysis by removal of this study did not markedly change the outcomes. It is unclear why DBP and HDL were significantly different because of study effect, but this result may have been related in part to the prediabetes entry criteria of the one study of liraglutide.[29] None of the included studies could report whether the body weight gain was specifically attributable to antipsychotic use. The included studies did not use easily comparable psychotic symptom-rating scales, making psychotic symptoms impractical to assess as an outcome. Study durations were too short to evaluate comparative risks of major adverse cardiovascular endpoints. We were only able to include 168 patients from three studies, which limits our ability to draw firm conclusions or infer clinical recommendations. We do not have data for older participants, and as such these results cannot be generalized to older adults on antipsychotic medications. Further studies are required in this population.

In conclusion, our findings suggest a promising role for GLP-1RA treatment for body weight management in patients with schizophrenia treated with clozapine or olanzapine; however, there are insufficient data to comment on the role of GLP-1RAs for those on other antipsychotics. GLP-1RA agents are also well-tolerated, with nausea being the most common ADR. The availability of a once-weekly injectable formulation may also offer advantages when compared with traditional body weight loss or diabetic medications requiring daily administration. However, obviously the availability of an oral formulation would increase the ease of use. While several body weight loss agents have been withdrawn because of adverse cardiac effects, GLP-1RAs are associated with lowering of cardiovascular mortality.[27] Our findings also suggest ancillary improvements in glucose homeostasis and visceral adiposity. While our data suggest that individuals taking clozapine or olanzapine may benefit most from GLP-1RAs with a less compelling argument for the use of GLP-1RAs for patients on other antipsychotics, this conclusion should be tempered by the fact that only one study included patients on antipsychotics other than clozapine and olanzapine. Further randomized clinical trials of GLP-1RAs in overweight or obese antipsychotic-treated patients with schizophrenia are required, particularly head-to-head trials comparing metformin and GLP-1RAs.

CONFLICT OF INTEREST

D. S. and P. L. I. have no interests to declare. S. K. has received speaker honoraria from Janssen. A. F.-J. has received an unrestricted research grant from Novo Nordisk. A. W. R. has received speaker honoraria and travel grants from Astra Zenica, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi, and has participated on advisory panels for MSD and Novo Nordisk. M. H. has participated on an advisory board for Alkermes. T. V. has no conflicts of interest to declare. F. K. K. has served on scientific advisory panels and/or Speaker's Bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gubra, MSD/Merck, Novo Nordisk, Sanofi and Zealand Pharma. B. H. E. has received lecture fees and/or is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia and Takeda Pharmaceutical Company. C. U. C. has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Angelini, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Merck, Neurocrine, Otsuka, Pfizer, ROVI, Servier, Sunovion, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, ROVI and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. J. L. and B. V. B. became a full-time employee at Novo Nordisk after completion of the clinical studies included in the meta-analysis. N. B. became a full-time employee at Lundbeck after completion of the clinical studies included in the meta-analysis.

ORCID

Dan Siskind https://orcid.org/0000-0002-2072-9216
Margaret Hahn https://orcid.org/0000-0001-8884-9946
Steve Kisely https://orcid.org/0000-0003-4021-2924
Bjørn H. Ebdrup https://orcid.org/0000-0002-2590-5055

REFERENCES

1. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry*. 2017;4:295-301.
2. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. *Br J Psychiatry*. 2010;196:116-121.
3. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. *BMJ*. 2013;346:f2539.
4. De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol*. 2012;8:114-126.
5. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. *Trends Mol Med*. 2011;17:97-107.
6. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013;382:951-962.

7. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry*. 2015;14:339-347.
8. Faulkner G, Cohn T, Remington G, Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. *J Schizophr Res*. 2007;90:174-178.
9. Young SJ, Praskova A, Hayward N, Patterson S. Attending to physical health in mental health services in Australia: a qualitative study of service users' experiences and expectations. *Health Soc Care Community*. 2017;25:602-611.
10. Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. *J Psychopharmacol*. 2016;30:717-748.
11. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet*. 2016;388:776-786.
12. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309:71-82.
13. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. *J Schizophr Res*. 2012;140:159-168.
14. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. *Neuropsychopharmacology*. 2010;35:1520-1530.
15. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med*. 2010;363:905-917.
16. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet*. 2007;370:1706-1713.
17. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2008;69:706-711.
18. Siskind D, Wysoczanski D, Russell A, Ashford M. Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine. *Aust N Z J Psychiatry*. 2016;50:702-703.
19. Zheng W, Li X-B, Tang Y-L, Xiang Y-Q, Wang C-Y, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. *J Clin Psychopharmacol*. 2015;35:499-509.
20. Zheng W, Xiang YT, Xiang YQ, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. *Acta Psychiatr Scand*. 2016;134:385-398.
21. Ebdrup BH, Knop FK, Ishøy PL, et al. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. *BMC Med*. 2012;10:92.
22. Smith GC, Vickers MH, Cognard E, Shepherd PR. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. *J Schizophr Res*. 2009;115:30-40.
23. Mayfield K, Siskind D, Winckel K, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. *J Psychopharmacol*. 2016;30:227-236.
24. Drucker DJ. The biology of incretin hormones. *Cell Metab*. 2006;3:153-165.
25. Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. *Front Neurosci*. 2015;9:92.
26. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. *Diabetes Care*. 2010;33:1173-1175.
27. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol*. 2018;6:105-113.
28. Ishøy PL, Knop FK, Broberg BV, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. *Diabetes Obes Metab*. 2017;19:162-171.
29. Larsen JR, Vedtofte L, Jakobsen MS, et al. Effect of Liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia Spectrum disorder: a randomized clinical trial. *JAMA Psychiat*. 2017;74:719-728.
30. Siskind D, Russell AW, Gamble C, et al. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial. *Diabetes Obes Metab*. 2018;20:1050-1055.
31. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. *Syst Rev*. 2012;1:2.
32. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester, England: John Wiley & Sons; 2011.
33. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. *Neuropsychopharmacology*. 2006;31:2318.
34. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? *J Schizophr Res*. 2005;79:231-238.
35. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ*. 2010;340:c221.
36. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. *Obes Res*. 1998;6(Suppl 2):51S-209S.
37. Barendregt JJ, Doi SA. *MetaXL User Guide. Version 5.3*. Sunrise Beach, Australia: EpiGear International Pty Ltd; 2016.
38. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ*. 2012;344:d7771.
39. Ebdrup BH, Broberg BV, Ishøy PL, et al. Erratum to: effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. *Diabetes Obes Metab*. 2018;20:1327-1328.
40. Ishiguro H, Kawaguchi K, Nishimura T, Toi M. Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy. *J Clin Oncol*. 2013;31:1377-1378.
41. Bustillo JR, Buchanan RW. Neuroleptic-induced emesis: a new indication for clozapine? *Biol Psychiatry*. 1995;38:194-195.
42. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. *Clin Ther*. 2011;33:528-576.
43. Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. *Lancet Diabetes Endocrinol*. 2018;6:237-248.
44. Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. *JAMA*. 2012;308:1150-1159.
45. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation*. 2007;116:39-48.
46. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. *Diabetes*. 2000;49:883-888.
47. Zhang Z-J, Yao Z-J, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. *Br J Psychiatry*. 2004;184:58-62.
48. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. *Am J Psychiatry*. 2004;161:361-363.
49. Oriot P, Feys JL, Mertens de Wilmars S, et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic

drugs: a nine-month prospective study. *Diabetes Metab*. 2008;34:490-496.
50. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. *Am J Psychiatry*. 2000;157:975-981.
51. Vinogradova Y, Coupland C, Hippisley-Cox J, Whyte S, Penny C. Effects of severe mental illness on survival of people with diabetes. *Br J Psychiatry*. 2010;197:272-277.
52. Jackson CT, Covell NH, Drake RE, Essock SM. Relationship between diabetes and mortality among persons with co-occurring psychotic and substance use disorders. *Psychiatr Serv*. 2007;58:270-272.
53. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *Br J Psychiatry*. 2016;209:385-392.
54. Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth S. The impact of clozapine on hospital use: a systematic review and meta-analysis. *Acta Psychiatr Scand*. 2017;135:296-309.
55. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S. Metformin for clozapine associated obesity: a systematic review and meta-analysis. *PLoS One*. 2016;11:e0156208.
56. Remington GJ, Teo C, Wilson V, et al. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. *J Endocrinol*. 2015;227:71-81.
57. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *J Gastroenterol Hepatol*. 2016;31:936-944.
58. Lonardo A, Nascimbeni F, Targher G, et al. AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. *Dig Liver Dis*. 2017;49:471-483.
59. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet*. 2016;387:679-690.
60. Committee for Medicinal Products for Human Use. *Guideline on Adjustment for Baseline Covariates in Clinical Trials*. London, UK: European Medicines Agency; 2015.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. *Diabetes Obes Metab*. 2019;21:293–302. https://doi.org/10.1111/dom.13522